AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01224912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment
Description: The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
Study NCT03756194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Socially-assistive Pepper robot with a CARESSES cultural competence solution
Description: Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. The robot will be culturally aware i.e., it will be aware of the participants' cultural background prior to the testing commencing. As such, it will pre-load the appropriate CKB and apply this during its time with the participants. During the next two sessions, the robot will interact and provide culturally-competent assistance, however, it will not learn and adjust to the participants' individual cultural values and preferences.~Week 2. The participants will again utilize the robot for three days, but it now will learn from the responses it receives from them, consequently interacting in a culture-specific personalised way.
Study NCT03756194 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Socially-assistive control Pepper robot with an alternative CARESSES solution
Description: Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. During the next two sessions, the CARESSES control robot will not be culturally aware: it will pre-load a generic and more limited CKB that is not tailored for anyone's cultural profile. It will also not learn and adjust to the participants' values and preferences.~Week 2. Participants will again utilize the robot for three days, but the CARESSES control robot will now be configured to be able to learn and adapt to the individual's particular profile. This robot's learning will not include propagation: improving its cultural knowledge base in one area will not also automatically lead to knowledge improvements in other related areas. This robot will possess the same full suite of functions as the CARESSES robot although will be less likely to offer these in a culturally appropriate way.
Study NCT01743651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen
Description: 40 mg/day as 20 mg arbaclofen ER administered orally 2 times per day
Study NCT01743651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: baclofen
Description: 80 mg/day as 20 mg baclofen administered orally 4 times per day
Study NCT01743651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
Study NCT04377997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease9, 10 and the association between coagulopathy and adverse outcomes in patients with sepsis11, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy. Most patients will receive low molecular weight heparin however, unfractionated heparin (UFH) will be administered for those with morbid obesity or moderate to severe renal dysfunction.
Study NCT04377997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease9, 10 and the association between coagulopathy and adverse outcomes in patients with sepsis11, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy. Most patients will receive low molecular weight heparin however, unfractionated heparin (UFH) will be administered for those with morbid obesity or moderate to severe renal dysfunction.
Study NCT04651738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DNA methylation testing
Description: Methylation testing of host DNA, namely, BHLHE22, CELF4, HAND2, and ZNF177
Study NCT00755755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001 (ulipristal) and iron
Description: tablets
Study NCT00755755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PGL4001 matching placebo and iron
Description: tablets
Study NCT00755755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001 (ulipristal) and iron
Description: Tablets
Study NCT01145144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dehydroepiandrosterone crystalline fine powder
Study NCT04701502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid
Description: Patients received daily doses of 30 ml of Viusid every 8 hours plus standard care for COVID-19. Viusid is administered orally.~Treatment duration: 21 days
Study NCT00362687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada (TDF+FTC) alone
Description: tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation
Study NCT00362687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC alone
Description: emtricitabine 200 mg
Study NCT00362687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No HAART
Description: No HAART
Study NCT02607163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
Study NCT02607163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
Study NCT03151668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT00353119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Patients received placebo subcutaneously twice weekly
Study NCT00353119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Patients received etanercept 50 mg subcutaneously twice weekly
Study NCT00353119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etanercept
Description: Patients received etanercept 50 mg subcutaneously twice weekly
Study NCT00423670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa 2b (PegIntron)
Description: 1.5 μg/kg subcutaneously (SC) once weekly (QW)
Study NCT00423670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: 200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
Study NCT00423670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
Study NCT04701502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Asbrip
Description: Patients received daily doses of 10 ml of Asbrip every 8 hours plus standard care for COVID-19. Asbrip is administered orally.~Treatment duration: 21 days
Study NCT04701502 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard Care
Description: Standard care for COVID-19
Study NCT04701502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard care for COVID-19
Study NCT02531438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: Injection for IV; Oral tablets
Study NCT02531438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: IV solution; Oral tablets
Study NCT02743663 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchodilator response
Description: Bronchodilator (Salbutamol - dose dependent on participant prescription) to wheezing subjects. 15 minutes after bronchodilator, spirometry and FOT repeated.
Study NCT02743663 — intervention group
Intervention type: PROCEDURE
Intervention: Allergy Skin Test
Description: Child will be tested for allergies to 17 different allergens, and positive (histamine) and negative (glycerin) controls, for a total of 19 allergens.
Study NCT02743663 — intervention group
Intervention type: PROCEDURE
Intervention: Multiple-Breath Washout
Description: Facemask in children 3-5 yrs, Wash-in phase: medical air inhaled during tidal breathing until steady state. Bias flow switched to 100% oxygen. Wash-out phase: patient breathes in 100% oxygen until nitrogen levels reach \~2%. Each test in duplicate and average is calculated.
Study NCT02743663 — intervention group
Intervention type: PROCEDURE
Intervention: Forced Oscillation Technique
Description: Sterile mouthpiece attached to FOT device. Patient is tested seated with noseclips and mouthpiece. FOT device produces oscillations at different frequencies (from that flow into lungs. Device measures resistance and reactance in lungs.
Study NCT02743663 — intervention group
Intervention type: PROCEDURE
Intervention: Spirometry
Description: Forced exhale manoeuvre completed by participant into flow meter, measuring forced exhale volumes and speed.
Study NCT00158652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy 70 Gy in 7 weeks
Description: 2 gy per fraction, 1 fraction per day, 5 fractions per week
Study NCT00158652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: middle accelerated radiotherapy 70 Gy in 6 weeks
Description: 5 x 2gy/week until 40 Gy in 20 fractions and 4 weeks, then 2 fractions of 1.5Gy per day for 30 additional Gy in 2 weeks
Study NCT00158652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: very accelerated radiotherapy 64.8 Gy in 3.5 weeks
Description: 2 fractions of 1.8 Gy per day for 64.8 Gy in 3.5 weeks
Study NCT00158652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU, Paraplatin
Description: 5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
Study NCT00158652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU, Paraplatin
Description: 5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
Study NCT01954121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Immediate release film-coated tablets at strengths of 250 mg and 500 mg.~* Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid~* Down-titration Period (Week 30 up to Week 33)
Study NCT01954121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Immediate release tablets at a strength of 200 mg.~* Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid~* Down-titration Period (Week 30 up to Week 33)
Study NCT02120651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin monomer
Description: Fibrin monomer by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
Study NCT02120651 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hemostatic sponge
Description: Hemostatic sponge by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
Study NCT03168035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC-4016
Description: Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.
Study NCT01170715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: self-administered for 52 weeks
Study NCT04262739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYH817G
Description: Subject will orally administer NYH817G (15 mg) during the cycles(21 days)
Study NCT04262739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYH100P
Description: Subject will orally administer NYH100P (100 mg) during the cycles(21 days)
Study NCT04262739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYH817G and NYH100P
Description: Subject will orally administer NYH817G (15 mg) and NYH100P (100 mg) during the cycles(21 days)
Study NCT02212457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero
Description: Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB_0_2 Group.
Study NCT02212457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.
Study NCT02212457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
Study NCT00423670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (low-dose)
Description: 200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
Study NCT02028338 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo ring
Description: intravaginal ring silicone elastomer intravaginal ring containing no drug product
Study NCT01729260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.
Study NCT03190369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 (GZ402662/SAR402662)
Description: Pharmaceutical form: Solution for injection~Route of administration: Intra articular
Study NCT03190369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Intra articular
Study NCT04840173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: During attendance at a one hour, 6-week psychosocial classroom or virtual training, caregivers will learn to use singing and other music-based interventions, implementing them each week before the informational session.
Study NCT03517124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceramic tooth restoration
Description: Dental restorations
Study NCT03517124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ceramic tooth restoration
Description: Dental restorations
Study NCT01387399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion
Description: Classical 3+3 dose escalation study of cisplatin administered as HIPEC (60mg/m², 80mg/m² and 100mg/m²)
Study NCT02028338 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dapivirine ring
Description: intravaginal ring silicone elastomer intravaginal ring containing 25 mg dapivirine
Study NCT03912571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Structural 3T MRI
Description: measures of global and hippocampal atrophy)
Study NCT01348607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate hydrochloride
Description: Given orally
Study NCT01348607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: Given orally
Study NCT01348607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02197793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization Program
Study NCT00567593 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosiglitazone
Description: 8mg tablet once a day for 14 days
Study NCT02476422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium
Description: Single dose of diclofenac 50 mg soft gelatin capsule
Study NCT02476422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Single dose of ibuprofen 400 mg tablet
Study NCT02476422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ibuprofen
Description: Single dose of placebo to ibuprofen 400 mg tablet
Study NCT02476422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to diclofenac potassium
Description: Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
Study NCT02743663 — intervention group
Intervention type: DRUG
Intervention: salbutamol
Description: Given during bronchodilator response.
Study NCT02743663 — intervention group
Intervention type: PROCEDURE
Intervention: Nasal Brush
Description: Nasal brush of 1 inferior turbinate to collect epithelial cells. Collected on either nare, choice dependent on how clear the nare is (i.e. no mucous, no nasal mucosal edema, no major structural impediments).
Study NCT02743663 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: 8mLs of venous blood collected using a butterfly needle of appropriate gauge. Blood sample used to collect CBC values, total IgE, serum, DNA, plasma, and whole blood.
Study NCT02743663 — intervention group
Intervention type: PROCEDURE
Intervention: Basophil activation test
Description: Collect basophils from whole blood sample, and expose cells to food allergens in flow cytometry machine to measure allergic response, if any.
Study NCT02743663 — intervention group
Intervention type: PROCEDURE
Intervention: Nasal swab
Description: Gentle swabbing of both nasal openings to collect mucous sample for analysis of microbial contents (i.e. bacteria, virus, fungi).
Study NCT03671993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical pudendal nerve stimulation
Description: Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum). Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45\~55 mA). EPNS was given for 60 min a time, 3 sessions per week for 6 weeks.
Study NCT03671993 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical instillation
Description: The patient should lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine should be drained. A mixture of the Cystistat (sodium hyaluronate, 50ml 40mg, Bioniche Teoranta, Ireland) solution and Lidocaine hydrochloride (40mg :20ml, Fangming Pharmacy company, Shangdong, China) is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the mixture solution inside the bladder, retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at 6 weeks.
Study NCT01859143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: A single dose of 10\^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
Study NCT01859143 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
Study NCT05702866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcutaneous oximetry
Description: Comparison of the TcpO2 values recorded during dynamic maneuver with the estimated rate of compression of the subclavian and axillary vessels determined on dynamic angiography.
Study NCT00689598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg po qd 25 mg po bid
Study NCT00689598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spironolactone
Description: 25 mg po qd 25 mg po bid
Study NCT00689598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Spironolactone 25 mg po qd